Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. QTI
QTI logo

QTI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy QT Imaging Holdings Inc (QTI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.820
1 Day change
-1.52%
52 Week Range
14.400
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

QT Imaging Holdings Inc (QTI) is not a strong buy at the moment for a beginner, long-term investor. While the company shows potential with its innovative technology and analyst optimism, the lack of positive trading signals, weak technical indicators, and concerning financial performance suggest waiting for clearer signs of growth or stability before investing.

Technical Analysis

The MACD histogram is negative (-0.01), indicating bearish momentum. RSI is at 28.62, which is neutral and does not suggest a strong buying opportunity. Moving averages are converging, showing no clear trend. Support and resistance levels indicate limited price movement in the short term.

Positive Catalysts

  • Analyst coverage initiated with a Buy rating and a $10 price target, citing the company's unique 3D imaging technology as a potential game-changer in breast cancer screening. Appointment of Dr. Mary W. Yamashita as Medical Advisor to enhance clinical integration.

Neutral/Negative Catalysts

  • Technical indicators do not support a strong buying opportunity. Stock trend analysis suggests limited short-term upside potential.

Financial Performance

In Q4 2025, revenue increased significantly by 877.56% YoY to $8,275,000. However, net income dropped to -$1,387,000, EPS fell to -0.1, and gross margin decreased to 37.97%. The financials indicate revenue growth but worsening profitability metrics.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Lake Street initiated coverage with a Buy rating and a $10 price target, highlighting the company's innovative QT Scan technology as a 'massive homerun opportunity' in breast cancer screening.

Wall Street analysts forecast QTI stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast QTI stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 5.910
sliders
Low
0
Averages
0
High
0
0
Current: 5.910
sliders
Low
0
Averages
0
High
0
Lake Street
NULL
to
Buy
initiated
$10
AI Analysis
2026-01-30
Reason
Lake Street
Price Target
$10
AI Analysis
2026-01-30
initiated
NULL
to
Buy
Reason
Lake Street initiated coverage of QT Imaging with a Buy rating and $10 price target. The company's QT Scan delivers true 3D imaging of breast tissue and offers unique characteristics, making it highly attractive to patients and clinicians, the analyst tells investors. The "massive homerun opportunity" for QT is to become a significant modality within breast cancer screening, the analyst added.

People Also Watch